Updated Data Reinforce EV-302 Regimen as SOC in Advanced Urothelial Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 60
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2025 AND VI 26 AND IP 4
Results: 19
1
2
Perioperative Durvalumab Shows Benefits in MIBC Irrespective of pCR Status.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 59
- By:
- Publication type:
- Article
3
Talazoparib Plus Enzalutamide Yields OS Improvement in mCRPC Supporting the Regimen as a SOC.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 55
- By:
- Publication type:
- Article
4
Targeted CAR T-Cell Therapies Show Early Efficacy in Solid Tumors With Focus on Mitigating Toxicity.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 53
- By:
- Publication type:
- Article
5
AI-POWERED SCOUT PLATFORM: Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 46
- By:
- Publication type:
- Article
6
Inflation Reduction Act Leads to Seesaw Effect Between Oncologic Drug Savings and Development.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 44
- By:
- Publication type:
- Article
7
PERSONALIZING Lung Cancer Treatment Reduces Toxicity and Improves Cure Rates.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 38
- By:
- Publication type:
- Article
8
Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 36
- By:
- Publication type:
- Article
9
RAS(ON) Inhibitors May Overcome Resistance to Traditional KRAS Inhibitors in Solid Tumors.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 33
- By:
- Publication type:
- Article
10
New ADCs Aim to Strengthen the HER2+ Breast Cancer Paradigm and Join T-DXd and T-DM1.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 28
- By:
- Publication type:
- Article
11
Targeted Treatments Shift the Paradigm of Advanced BTC.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 20
- By:
- Publication type:
- Article
12
Ensartinib Looks to Find a Place in ALK+ NSCLC Paradigm Alongside Approved TKIs.
- Published in:
- 2025
- By:
- Publication type:
- Interview
13
Sotorasib Plus Panitumumab Receives Indication for KRAS G12C-Mutated CRC.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 12
- Publication type:
- Article
14
FDA Gives Acalabrutinib Plus Bendamustine and Rituximab Go-Ahead for Previously Untreated MCL.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 12
- Publication type:
- Article
15
Subcutaneous Nivolumab Receives Green Light in Advanced or Metastatic Solid Tumors.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 12
- Publication type:
- Article
16
Tislelizumab Plus Chemo Gains Indication for PD-L1+Unresectable or Metastatic Gastric/GEJ Cancer.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 12
- Publication type:
- Article
17
Encorafenib/Cetuximab/Chemo Receives Accelerated Approval for BRAF V600E+mCRC.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 12
- Publication type:
- Article
18
"HALFWAY TECHNOLOGY" Is It Time to Seriously Discuss Transitioning From the Current Focus of Cancer Research?
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 10
- By:
- Publication type:
- Article
19
Gearing Up for Spring Conferences Key Updates, Expert Insights, and Latest Breakthroughs.
- Published in:
- OncologyLive, 2025, v. 26, n. 4, p. 8
- By:
- Publication type:
- Article